Revance Therapeutics, Inc. - RVNC STOCK NEWS

Revance Therapeutics, Inc. (NASDAQ: RVNC) will participate in the 22nd Annual Needham Virtual Healthcare Conference from April 17-20, 2023. CFO Tobin Schilke is set to engage in a fireside chat on April 18 at 12:45 PM ET. The conference's live audio webcast can be accessed via the company's Investor Relations page, with a replay available for 90 days post-event. Revance focuses on innovative aesthetic and therapeutic solutions, including the DAXXIFY® injection for muscle movement disorders. Headquartered in Nashville, Tennessee, Revance also operates in Newark, Pleasanton, and Irvine, California.

Revance Therapeutics, Inc. (RVNC) announced its participation in upcoming investor conferences. CEO Mark J. Foley will engage in a fireside chat at the Barclays Global Healthcare Conference on March 14 at 9:00 A.M. ET in Miami, Florida. CFO Tobin Schilke will speak at the Guggenheim Healthy Altitudes Summit on March 16 at 7:45 A.M. MT in Telluride, Colorado. Live webcasts can be accessed via the Investor Relations section of Revance's website, with replays available for 90 days post-event.

Revance specializes in innovative aesthetic and therapeutic solutions, including DAXXIFY® and the RHA® Collection, enhancing patient and physician experiences.

The facial injectable market was valued at US$8.606 billion in 2020, projected to reach US$23.549 billion by 2027 with a CAGR of 15.46%. This growth is driven by an aging population and rising interest in minimally invasive procedures. Market players like Revance Therapeutics, Inc. (RVNC) are capitalizing on this trend, having signed a U.S. distribution agreement with TEOXANE SA to market their hyaluronic acid fillers. The FDA is reviewing DaxibotulinumtoxinA Injection, signifying ongoing innovation. Despite this growth, challenges include potential adverse effects and regulatory issues surrounding botulinum toxin use.

Revance Therapeutics, Inc. (RVNC) reported Q4 2022 total revenue of $49.9 million, a 92% year-over-year increase, while full-year revenue reached $132.6 million, up 70%. The RHA® Collection drove $34.8 million in quarterly revenue, and DAXXIFY® generated $11.0 million during its PrevU program. Despite revenue growth, operating expenses surged to $194.3 million for Q4, impacted by a $69.8 million goodwill impairment. The company anticipates 2023 operating expenses of $460 million to $480 million. DAXXIFY® is set to launch commercially in late March 2023, with a PDUFA date for cervical dystonia on August 19, 2023.

Revance Therapeutics (RVNC) appointed Dr. Vlad Coric to its Board of Directors, effective March 1, 2023. Dr. Coric, with over 22 years of experience in drug development, previously served as Chairman and CEO of Biohaven. He is credited with the successful commercialization of Nurtec® ODT and played a key role in Biohaven's acquisition by Pfizer for $13 billion. Revance's CEO, Mark J. Foley, highlighted Dr. Coric's expertise as beneficial during a pivotal time for the company, focusing on both aesthetic and therapeutic growth, particularly with DAXXIFY®. Additionally, Dr. Philip Vickers is retiring from the Board ahead of the annual meeting.

Revance Therapeutics, Inc. (RVNC) will participate in the 43rd Annual Cowen Healthcare Conference from March 6-8, 2023, in Boston, Massachusetts. CEO Dustin S. Sjuts and CFO Tobin Schilke will engage in a fireside chat on Monday, March 6 at 9:50 A.M. EST. Interested viewers can access the live audio webcast through the Investor Relations section of their website, with a replay available for 90 days post-event. Revance focuses on developing innovative aesthetic and therapeutic solutions, including DAXXIFY® and a biosimilar to onabotulinumtoxinA, targeting muscle movement disorders.

Revance Therapeutics, Inc. (RVNC) announced promising new data for DAXXIFY®, a treatment for cervical dystonia, to be presented at the Association of Academic Physiatrists annual meeting from February 21-24, 2023. The findings from 382 patients over 88 weeks showed a duration of efficacy lasting 20-26 weeks with a low adverse event rate. Dysphagia rates were reported at 2.7% and 4.2% in two studies. Dr. David A. Hollander emphasized the sustained effectiveness and safety of DAXXIFY® across multiple treatment cycles, which could enhance therapeutic options for cervical dystonia sufferers. Regulatory review by the FDA is currently underway.